Experts warn RSV could join Covid and flu winter virus mix

At the start of the autumn, experts warned that the UK could be hit by two viruses this winter, Covid and flu. Also known as a twindemic, this caused great concern among both the health and scientific community amid fears it could put pressure on the NHS and the health system as a whole. Fast forward to November and experts are warning of a ‘tripledemic’ of flu, COVID-19 and, RSV.

However, before we understand those conditions, it is key to understand what a tripledemic is. A tripledemic is like a twindemic except instead of two waves of two viruses hitting at the same time, three waves of three viruses hit at the same time.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    The Annual Flu Jab: How do we know it’s effective?

    Each year studies are performed to determine how well Flu Jabs are protecting members of the public from influenza. While each year varies in the strain of influenza circulating and the effectiveness of the vaccine at fighting the

    hVIVO plc

    Alexander Mann speaking at World Antiviral Congress 2022

    Alexander Mann | Senior Director, Clinical Sciences Alex Mann has a specific interest in the use of human challenge models to answer key questions around host responses to infection as well as efficacy of treatments and vaccines. Over the last

    hVIVO plc

    Human Challenge Studies: Their conduct and safety aspect

    If there would be a survey of 100 clinical research professionals either from CRO or from Pharma/Biotech industry to explain what a human challenge study is, the most common answer most probably would be – “I have never heard of

    hVIVO plc

    FluCamp interview Research Nurse Claudia Machado

    hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

    hVIVO plc

    hVIVO Chairman Cathal Friel shares his thoughts on £13.6m contract

    hVIVO plc (LON:HVO) announced that it has signed a £13.6m contract with a US-based biopharmaceutical client to test its respiratory syncytial virus antiviral candidate, using hVIVO’s established RSV Human Challenge Study Model. “I am delighted to announce that

    hVIVO plc

    Key leanings from the RSV challenge model and efficacy of vaccines

    hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

    hVIVO plc

    Scale-up and scale-down approaches in biologics

    Appropriate scale-up/down is key for further larger production. Important is to focus to the right parameters that can help us to set the design for all experiments at lab scale.The common approach within the up-stream processing (USP) part

    Open Orphan Plc

    Open Orphan name change to hVIVO effective 26th October 2022

    Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that further to its announcement on 8 September 2022, the Company’s